期刊文献+

美罗华联合化疗治疗儿童弥漫大B细胞淋巴瘤1例 被引量:1

原文传递
导出
摘要 患儿,男,9岁,因间断性腹痛半年余入院。体格检查:双侧颈部可触及4枚肿大淋巴结,大小约1.0cm×1.5cm,活动度可、质硬、无触痛。腹胀,脐周可触及-肿物,大小约6.0cm×5.0cm×5.0cm。血常规示WBC15.1×10^9/L,
出处 《中国当代儿科杂志》 CAS CSCD 北大核心 2012年第5期387-388,共2页 Chinese Journal of Contemporary Pediatrics
  • 相关文献

参考文献7

  • 1Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe M J, et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent e-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group[ J]. Pediatr Blood Cancer, 2008, 51(3): 369-374.
  • 2Winter JN, Weller EA, Homing SJ, Krajewska M, Variakojis D, Habennann TM, et al. Prognostic significance of Bel-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study[ J]. Blood, 2006, 107 ( 11 ) :4207-4213.
  • 3Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipeh G, Rummel MJ, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases [ J ]. Haematologica, 2002, 87 ( 1 ) : 33-43.
  • 4Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berqlund M, Amini RM, et al:- Prognostic impact of immunohisto- chemically defined germinal center phenotype in diffuse large Bcell lymphoma patients treated with immunochemotherapy [ J ]. Blood, 2007, 109(11 ): 4930-4935.
  • 5Fang C, Xu W, Li JY. A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma[ J ]. Ann Hematol, 2010, 89 ( 11 ) : 1107-1113.
  • 6Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, et al. A study of rituximab and ifosfamide, carboplatin, and eto- poside chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia : a report from the Children's Oncology Group [ J ]. Pediatr Blood Cancer, 2009, 52(2) : 177-181.
  • 7Shabbal S, Aharoni J, Sarid L, Ben-Harush M, Kapelushnik J. Rituximab as monotherapy and in addition to reduced CHOP in children with primary immunodeficiency and non-Hodgkin lymphoma[J]. Pediatr Blood Cancer, 2009, 52(5) : 664-666.

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部